OBJECTIVE
To review the clinical features associated with hyperglucagonemia in malignant neuroendocrine tumors.
METHODS
We retrospectively reviewed the medical records of patients with hyperglucagonemia encountered at our institution from Oct. 17, 1988, through February 1993 who had a fasting serum